Is Apolipoprotein B Assessment Ready for Prime Time?

In a large cohort analysis, apoB was the only lipid parameter independently associated with risk for myocardial infarction.

Apolipoprotein B (apoB)–containing lipoproteins have a causal role in atherogenesis. In this prospective cohort study, investigators used data from the U.K. Biobank and two large clinical trials — FOURIER (NCT01764633) and IMPROVE-IT (NCT00202878) — to test associations between apoB, non–high-density lipoprotein cholesterol (non–HDL-C), low-density lipoprotein cholesterol (LDL-C), and triglycerides and risk for incident myocardial infarction (MI).

There were two study populations: A primary prevention cohort consisting of 389,529 patients not taking lipid-lowering therapy and a secondary prevention cohort including 40,430 patients with a history of atherosclerosis and taking statins.

After a median follow-up of 11 years in the primary prevent…

Reviewing Author

Fatima Rodriguez, MD, MPH, FACC, FAHA

Disclosures

Consultant/Advisory BoardNovoNordisk; HealthPals; Novartis; Amgen

EquityHealthPals; Carta

Grant/Research SupportNational Institutes of Health/National Heart, Lung, and Blood Institute; American Heart Association–Robert Wood Johnson Foundation

Editorial BoardsCardiology and Therapy